Rita Azevedo graduated in Biochemistry from the Instituto Universitário de Ciências of CESPU group in 2012. She started her research pathway in the field of pharmacogenetics by integrating the Molecular Oncology Group & Viral Pathology – Research Centre, Portuguese Institute of Oncology – Porto, for two years. Rita Azevedo completed an MSc in Medical Informatics in 2014 from the Faculty of Medicine of the University of Porto, with a dissertation about mobile health (mHealth) for disease self-management. In 2014 she started her PhD degree in Pathology and Molecular Genetics at the Abel Salazar Biomedical Sciences Institute of the University of Porto aimed to develop novel therapeutic strategies based on glycoproteins in bladder cancer, with funding from a grant from the Foundation for the Science and Technology (FCT) (SFRH/BD/105355/2014). She also joined the Experimental Pathology and Therapeutics Group of the Portuguese Institute of Oncology – Porto, the host institution where the PhD work has been developed. Her thesis has set a roadmap for glycobiomarker discovery in bladder cancer (cell lines, biopsies, and urine samples), exploring the full potential of glycomics, glycoproteomics, and high-resolution mass spectrometry. Moreover, it has set the foundations for glycoepitopes synthesis and purification, providing the necessary structural and clinical rationale for supporting the development of novel glycan-based theranostics applications. In 2020, Rita Azevedo had her first abroad experience and started as a post-doctoral researcher in the Pulliainen-laboratory at the University of Turku, Finland. She was interested in conducting proteomics in Salmonellosis models and exploring ADP-ribosylation using high-resolution mass spectrometry (DDA). In 2021, she moved to France and started as a research engineer in the François Becher group at CEA Saclay, Ille-de-France. She characterized and quantified tau protein in Alzheimer’s disease using high-resolution mass spectrometry (DDA and PRM), aiming to find novel tau proteoforms as biomarkers. At two months before the end of 2022, she joined as a research engineer to Matondo’s Proteomics Platform, Mass Spectrometry for Biology Utechs (MSBio), Institut Pasteur.